PriZm Therapeutics is focused on developing innovative therapies for ultra-rare pediatric orphan diseases, specifically targeting conditions like MCT8 deficiency (AHDS). The company is advancing its lead product, SRW101, which is a first-in-class treatment designed to address the unique challenges posed by this genetic disorder that predominantly affects boys. PriZm is currently preparing to initiate a phase III pivotal registration clinical trial for SRW101, aiming to provide eligible patients with timely access to this investigational drug. The trial will be listed on ClinicalTrials.gov, ensuring transparency and accessibility for those interested in participating.

The company emphasizes its commitment to improving the quality of life for patients suffering from rare genetic disorders through rigorous clinical development. By focusing on a targeted approach, PriZm Therapeutics aims to address the unmet medical needs of children affected by MCT8 deficiency, showcasing its dedication to advancing human health through innovative solutions. The upcoming clinical trial represents a significant step in the company's mission to bring effective treatments to market for these vulnerable patient populations.

United States

PriZm Therapeutics is a late-stage clinical biotech company developing therapies for ultra-rare pediatric orphan diseases.

priZm Therapeutics

Company Details